

Christian Hlscher

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6299913/christian-holscher-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

197
papers

11,847
citations

61
h-index

103
g-index

211
ext. papers

13,785
ext. citations

4.7
avg, IF

7.14
L-index

#	Paper	IF	Citations
197	Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. <i>EMBO Reports</i> , 2006 , 7, 940-6	6.5	626
196	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. <i>Journal of Clinical Investigation</i> , 2012 , 122, 1339-53	15.9	567
195	The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. <i>Journal of Neuroscience</i> , 2011 , 31, 6587-94	6.6	460
194	Stimulation on the positive phase of hippocampal theta rhythm induces long-term potentiation that can be depotentiated by stimulation on the negative phase in area CA1 in vivo. <i>Journal of Neuroscience</i> , 1997 , 17, 6470-7	6.6	343
193	Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity. <i>Trends in Neurosciences</i> , 1997 , 20, 298-303	13.3	342
192	Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. <i>CNS Drugs</i> , 2013 , 27, 505-14	6.7	329
191	Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. <i>BMC Neuroscience</i> , 2012 , 13, 33	3.2	297
190	Common pathological processes in Alzheimer disease and type 2 diabetes: a review. <i>Brain Research Reviews</i> , 2007 , 56, 384-402		277
189	Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology. <i>Brain</i> , 2016 , 139, 891-907	11.2	265
188	TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's amyloid oligomers in mice and monkeys. <i>Cell Metabolism</i> , 2013 , 18, 831-43	24.6	258
187	Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. <i>Neuropharmacology</i> , 2014 , 76 Pt A, 57-67	5.5	216
186	Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. <i>Behavioural Brain Research</i> , 2009 , 205, 265-71	3.4	195
185	Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. <i>Journal of Endocrinology</i> , 2014 , 221, T31-41	4.7	191
184	Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. <i>NeuroReport</i> , 2009 , 20, 1161-6	1.7	180
183	Stress impairs performance in spatial water maze learning tasks. <i>Behavioural Brain Research</i> , 1999 , 100, 225-35	3.4	170
182	Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. <i>Journal of Neuroscience Research</i> , 2011 , 89, 481-9	4.4	150
181	An inhibitor of nitric oxide synthesis prevents memory formation in the chick. <i>Neuroscience Letters</i> , 1992 , 145, 165-7	3.3	141

180	Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. <i>Journal of Neurophysiology</i> , 2001 , 85, 708-13	3.2	132
179	Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. <i>Neurobiology of Aging</i> , 2012 , 33, 265-76	5.6	130
178	Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2010 , 630, 158-62	5.3	130
177	The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. <i>Journal of Pathology</i> , 2018 , 245, 85-100	9.4	127
176	Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. <i>CNS Drugs</i> , 2012 , 26, 871-82	6.7	122
175	Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. <i>Neuroscience</i> , 2015 , 303, 42-50	3.9	118
174	Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. <i>Biochemical Society Transactions</i> , 2011 , 39, 891-7	5.1	116
173	Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 891-9	6.7	116
172	GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. <i>European Journal of Pharmacology</i> , 2008 , 587, 112-7	5.3	116
171	GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. <i>Reviews in the Neurosciences</i> , 2011 , 23, 1-11	4.7	114
170	Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease. <i>PLoS ONE</i> , 2015 , 10, e0119452	3.7	105
169	Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. <i>Journal of Neurochemistry</i> , 2014 , 128, 459-71	6	104
168	The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid- β plaque and glial pathology in a mouse model of Alzheimer's disease. <i>NeuroMolecular Medicine</i> , 2013 , 15, 102-14	4.6	103
167	Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice. <i>PLoS ONE</i> , 2010 , 5, e9764	3.7	103
166	Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. <i>Neuropharmacology</i> , 2014 , 86, 241-58	5.5	99
165	Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease. <i>Analytical Chemistry</i> , 2013 , 85, 1803-11	7.8	99
164	The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's disease. <i>Brain Research</i> , 2012 , 1449, 83-93	3.7	97
163	Liraglutide protects against amyloid- β protein-induced impairment of spatial learning and memory in rats. <i>Neurobiology of Aging</i> , 2013 , 34, 576-88	5.6	96

162	Synaptic plasticity and learning and memory: LTP and beyond. <i>Journal of Neuroscience Research</i> , 1999 , 58, 62-75	4.4	91
161	Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. <i>Neurobiology of Disease</i> , 1998 , 5, 129-41	7.5	90
160	Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models. <i>Neuropharmacology</i> , 2018 , 136, 251-259	5.5	86
159	The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, S47-54 ^{1,2}	1.2	86
158	Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. <i>Recent Patents on CNS Drug Discovery</i> , 2010 , 5, 109-17		80
157	Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. <i>Journal of Neurophysiology</i> , 2011 , 105, 1574-80	3.2	77
156	Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. <i>PLoS ONE</i> , 2013 , 8, e58784	3.7	75
155	Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. <i>International Journal of Obesity</i> , 2010 , 34, 1341-4	5.5	74
154	The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. <i>European Journal of Pharmacology</i> , 2013 , 700, 42-50	5.3	73
153	Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice. <i>Behavioural Brain Research</i> , 2015 , 293, 96-106	3.4	71
152	Lack of the metabotropic glutamate receptor subtype 7 selectively impairs short-term working memory but not long-term memory. <i>Behavioural Brain Research</i> , 2004 , 154, 473-81	3.4	71
151	Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease. <i>European Journal of Pharmacology</i> , 2015 , 768, 21-7	5.3	70
150	Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome. <i>Neurobiology of Aging</i> , 2016 , 38, 151-163	5.6	70
149	New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?. <i>Neurobiology of Aging</i> , 2010 , 31, 1495-502	5.6	70
148	Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases. <i>Biochemical Society Transactions</i> , 2014 , 42, 593-9	5.1	69
147	Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. <i>Journal of Neurophysiology</i> , 2008 , 99, 1590-5	3.2	69
146	Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies. <i>Reviews in the Neurosciences</i> , 2005 , 16, 181-212	4.7	68
145	Reward modulates neuronal activity in the hippocampus of the rat. <i>Behavioural Brain Research</i> , 2003 , 142, 181-91	3.4	68

144	Time, space and hippocampal functions. <i>Reviews in the Neurosciences</i> , 2003 , 14, 253-84	4.7	68
143	Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer's Disease. <i>Metabolites</i> , 2017 , 7,	5.6	67
142	A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. <i>Behavioural Brain Research</i> , 2017 , 327, 65-74	3.4	65
141	Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease. <i>Brain Research</i> , 2018 , 1678, 64-74	3.7	65
140	A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APP ^{swe} /PS1 ^{E9} mouse model of Alzheimer's disease. <i>PLoS ONE</i> , 2013 , 8, e54769	3.7	65
139	(Val) ¹ glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. <i>European Journal of Pharmacology</i> , 2012 , 674, 280-6	5.3	62
138	A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BDNF. <i>Brain Research</i> , 2016 , 1634, 1-11	3.7	61
137	Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. <i>European Journal of Pharmacology</i> , 2007 , 561, 85-90	5.3	61
136	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). <i>Trials</i> , 2019 , 20, 191	2.8	57
135	Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice. <i>International Journal of Obesity</i> , 2013 , 37, 678-84	5.5	57
134	Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. <i>European Journal of Pharmacology</i> , 2011 , 650, 688-93	5.3	57
133	Perirhinal cortex neuronal activity related to long-term familiarity memory in the macaque. <i>European Journal of Neuroscience</i> , 2003 , 18, 2037-46	3.5	57
132	Metabotropic glutamate receptor activation and blockade: their role in long-term potentiation, learning and neurotoxicity. <i>Neuroscience and Biobehavioral Reviews</i> , 1999 , 23, 399-410	9	56
131	Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice. <i>Neuropharmacology</i> , 2014 , 86, 22-30	5.5	54
130	Quinolinic acid lesion of the rat entorhinal cortex pars medialis produces selective amnesia in allocentric working memory (WM), but not in egocentric WM. <i>Behavioural Brain Research</i> , 1994 , 63, 187-94	3.4	52
129	A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease. <i>European Journal of Pharmacology</i> , 2017 , 812, 82-90	5.3	51
128	Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease. <i>Neuropharmacology</i> , 2018 , 133, 385-394	5.5	50
127	First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, S33-7	1.2	49

126	Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, 20	9	49
125	Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model. <i>Neuropharmacology</i> , 2016 , 101, 255-63	5.5	48
124	Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model. <i>Neuropeptides</i> , 2018 , 71, 70-80	3.3	48
123	Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice. <i>European Journal of Pharmacology</i> , 2012 , 674, 294-306	5.3	47
122	The role of GLP-1 in neuronal activity and neurodegeneration. <i>Vitamins and Hormones</i> , 2010 , 84, 331-54	2.5	47
121	A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease. <i>Neuropharmacology</i> , 2017 , 117, 238-248	5.5	46
120	Metabolic signatures of human Alzheimer's disease (AD): 1H NMR analysis of the polar metabolome of post-mortem brain tissue. <i>Metabolomics</i> , 2014 , 10, 744-753	4.7	46
119	Semaglutide is Neuroprotective and Reduces β Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019 , 9, 157-171	5.3	45
118	A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain. <i>NeuroReport</i> , 2016 , 27, 384-91	1.7	45
117	D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model. <i>Journal of Alzheimer's Disease</i> , 2013 , 35, 267-83	4.3	45
116	Brain insulin resistance: role in neurodegenerative disease and potential for targeting. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 333-348	5.9	44
115	Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells. <i>Journal of Neurochemistry</i> , 2016 , 139, 55-67	6	44
114	Age-associated changes of brain copper, iron, and zinc in Alzheimer's disease and dementia with Lewy bodies. <i>Journal of Alzheimer's Disease</i> , 2014 , 42, 1407-13	4.3	44
113	Increased number of orexin/hypocretin neurons with high and prolonged external stress-induced depression. <i>Behavioural Brain Research</i> , 2014 , 272, 196-204	3.4	43
112	Therapeutic Potential of Baicalein in Alzheimer's Disease and Parkinson's Disease. <i>CNS Drugs</i> , 2017 , 31, 639-652	6.7	41
111	Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 88	5.3	41
110	Inhibitors of cyclooxygenases produce amnesia for a passive avoidance task in the chick. <i>European Journal of Neuroscience</i> , 1995 , 7, 1360-5	3.5	41
109	A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease. <i>Hippocampus</i> , 2018 , 28, 358-372	3.5	39

108	Lack of the metabotropic glutamate receptor subtype 7 selectively modulates Theta rhythm and working memory. <i>Learning and Memory</i> , 2005 , 12, 450-5	2.8	37
107	Inhibitors of phospholipase A2 produce amnesia for a passive avoidance task in the chick. <i>Behavioral and Neural Biology</i> , 1994 , 61, 225-32		37
106	Neuroprotective effects of glucose-dependent insulintropic polypeptide in Alzheimer's disease. <i>Reviews in the Neurosciences</i> , 2016 , 27, 61-70	4.7	36
105	Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice. <i>Peptides</i> , 2012 , 35, 1-8	3.8	36
104	DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2018 , 827, 215-226	5.3	35
103	Hepcidin treatment modulates the expression of divalent metal transporter-1, ceruloplasmin, and ferroportin-1 in the rat cerebral cortex and hippocampus. <i>Biological Trace Element Research</i> , 2011 , 143, 1581-93	4.5	35
102	Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25-35) are dependent on stimulation-protocol and genetic background. <i>Experimental Brain Research</i> , 2007 , 179, 621-30	2.3	35
101	A novel dual-glucagon-like peptide-1 and glucose-dependent insulintropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat. <i>NeuroReport</i> , 2016 , 27, 23-32	1.7	35
100	Neuroprotective effects of geniposide on Alzheimer's disease pathology. <i>Reviews in the Neurosciences</i> , 2015 , 26, 371-83	4.7	34
99	Inactivation of the rat dorsal striatum impairs performance in spatial tasks and alters hippocampal theta in the freely moving rat. <i>Behavioural Brain Research</i> , 2005 , 164, 73-82	3.4	34
98	Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model. <i>Behavioural Brain Research</i> , 2015 , 293, 107-13	3.4	33
97	¹ H NMR metabolomics investigation of an Alzheimer's disease (AD) mouse model pinpoints important biochemical disturbances in brain and plasma. <i>Metabolomics</i> , 2013 , 9, 974-983	4.7	33
96	D-Ala ² -GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BDNF expression while reducing neuroinflammation and lipid peroxidation. <i>European Journal of Pharmacology</i> , 2017 , 797, 162-172	5.3	32
95	Long-term potentiation: a good model for learning and memory?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1997 , 21, 47-68	5.5	32
94	Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide. <i>Microcirculation</i> , 2015 , 22, 133-45	2.9	31
93	Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells. <i>Scientific Reports</i> , 2017 , 7, 16158	4.9	31
92	GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes. <i>Peptides</i> , 2018 , 100, 101-107	3.8	30
91	The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke. <i>Neuropharmacology</i> , 2019 , 158, 107748	5.5	29

90	Activation of group-II metabotropic glutamate receptors blocks induction of long-term potentiation and depotentiation in area CA1 of the rat in vivo. <i>European Journal of Pharmacology</i> , 1997 , 322, 155-63	5.3	29
89	L-AP4 (L-(+)-2-amino-4-phosphonobutyric acid) induced impairment of spatial learning in the rat is antagonized by MAP4 ((S)-2-amino-2-methyl-4-phosphonobutanoic acid). <i>Behavioural Brain Research</i> , 1996 , 81, 69-79	3.4	28
88	Inhibitors of PLA2 and NO synthase cooperate in producing amnesia of a spatial task. <i>NeuroReport</i> , 1995 , 6, 730-2	1.7	28
87	Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of amyloid pathology. <i>Neuropharmacology</i> , 2019 , 144, 377-387	5.5	28
86	Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus. <i>Epilepsy Research</i> , 2018 , 142, 45-52	3	27
85	Lixisenatide attenuates the detrimental effects of amyloid β protein on spatial working memory and hippocampal neurons in rats. <i>Behavioural Brain Research</i> , 2017 , 318, 28-35	3.4	26
84	New animal models of Alzheimer's disease that display insulin desensitization in the brain. <i>Reviews in the Neurosciences</i> , 2013 , 24, 607-15	4.7	26
83	Magnolol alleviates Alzheimer's disease-like pathology in transgenic <i>C. elegans</i> by promoting microglia phagocytosis and the degradation of beta-amyloid through activation of PPAR- γ <i>Biomedicine and Pharmacotherapy</i> , 2020 , 124, 109886	7.5	26
82	Neural circuit interactions between the dorsal raphe nucleus and the lateral hypothalamus: an experimental and computational study. <i>PLoS ONE</i> , 2014 , 9, e88003	3.7	25
81	Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease. <i>European Journal of Pharmacology</i> , 2015 , 765, 284-90	5.3	24
80	Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain. <i>Brain Research</i> , 2012 , 1473, 204-13	3.7	24
79	Perirhinal cortex neuronal activity is actively related to working memory in the macaque. <i>Neural Plasticity</i> , 2002 , 9, 41-51	3.3	24
78	Inhibitors of metabotropic glutamate receptors produce amnestic effects in chicks. <i>NeuroReport</i> , 1994 , 5, 1037-40	1.7	24
77	The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 523-542	5.3	23
76	Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimer's and Parkinson's disease. <i>Cardiovascular Endocrinology</i> , 2016 , 5, 93-98		22
75	Coexistences of insulin signaling-related proteins and choline acetyltransferase in neurons. <i>Brain Research</i> , 2009 , 1249, 237-43	3.7	22
74	Wide-ranging alterations in the brain fatty acid complement of subjects with late Alzheimer's disease as detected by GC-MS. <i>American Journal of Translational Research (discontinued)</i> , 2016 , 8, 154-65 ³		22
73	GIP has neuroprotective effects in Alzheimer and Parkinson's disease models. <i>Peptides</i> , 2020 , 125, 17018 ⁴⁸		22

72	The novel GLP-1/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD. <i>Brain and Behavior</i> , 2020 , 10, e01505	3.4	21
71	Different strains of rats show different sensitivity to block of long-term potentiation by nitric oxide synthase inhibitors. <i>European Journal of Pharmacology</i> , 2002 , 457, 99-106	5.3	21
70	New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases. <i>Neural Regeneration Research</i> , 2014 , 9, 1870-3	4.5	20
69	Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases. <i>Acta Physiologica Sinica</i> , 2014 , 66, 497-510	1.3	20
68	Val ⁶⁸ GLP-1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid β peptide in rats. <i>Journal of Neuroscience Research</i> , 2013 , 91, 568-77	4.4	19
67	Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. <i>Reviews in the Neurosciences</i> , 2016 , 27, 689-711	4.7	18
66	Levo-tetrahydropalmatine inhibits the acquisition of ketamine-induced conditioned place preference by regulating the expression of ERK and CREB phosphorylation in rats. <i>Behavioural Brain Research</i> , 2017 , 317, 367-373	3.4	17
65	Prostaglandins play a role in memory consolidation in the chick. <i>European Journal of Pharmacology</i> , 1995 , 294, 253-9	5.3	17
64	Therapeutic Potential of Genipin in Central Neurodegenerative Diseases. <i>CNS Drugs</i> , 2016 , 30, 889-97	6.7	17
63	The Novel DA-CH3 Dual Incretin Restores Endoplasmic Reticulum Stress and Autophagy Impairments to Attenuate Alzheimer-Like Pathology and Cognitive Decrements in the APPSWE/PS1E9 Mouse Model. <i>Journal of Alzheimer's Disease</i> , 2018 , 66, 195-218	4.3	17
62	Integrating microRNA and messenger RNA expression profiles in a rat model of deep vein thrombosis. <i>International Journal of Molecular Medicine</i> , 2017 , 40, 1019-1028	4.4	16
61	Quantitative analysis of iron concentration and expression of ferroportin 1 in the cortex and hippocampus of rats induced by cerebral ischemia. <i>Journal of Clinical Neuroscience</i> , 2009 , 16, 1466-72	2.2	16
60	Anaesthesia generates neuronal insulin resistance by inducing hypothermia. <i>BMC Neuroscience</i> , 2008 , 9, 100	3.2	15
59	Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease. <i>Neuropharmacology</i> , 2020 , 162, 107813	5.5	15
58	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 47	9	14
57	Nitric oxide is required for expression of LTP that is induced by stimulation phase-locked with theta rhythm. <i>European Journal of Neuroscience</i> , 1999 , 11, 335-43	3.5	13
56	Dehydroabietic acid alleviates high fat diet-induced insulin resistance and hepatic steatosis through dual activation of PPAR- α and PPAR- β . <i>Biomedicine and Pharmacotherapy</i> , 2020 , 127, 110155	7.5	12
55	Learned association of allocentric and egocentric information in the hippocampus. <i>Experimental Brain Research</i> , 2004 , 158, 233-40	2.3	12

54	Beta-amyloid induced reduction in synaptic transmission is reversed by inhibitors of nitric oxide synthase. <i>NeuroReport</i> , 1998 , 9, 1245-8	1.7	12
53	Quantitative measurement of [Na ⁺] and [K ⁺] in postmortem human brain tissue indicates disturbances in subjects with Alzheimer's disease and dementia with Lewy bodies. <i>Journal of Alzheimer's Disease</i> , 2015 , 44, 851-7	4.3	11
52	Neuroprotective role of (Val(8))GLP-1-Glu-PAL in an in vitro model of Parkinson's disease. <i>Neural Regeneration Research</i> , 2016 , 11, 326-31	4.5	11
51	The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2020 , 35, 1533317520953041	2.5	11
50	Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. <i>British Journal of Pharmacology</i> , 2021 ,	8.6	11
49	Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis. <i>Journal of Natural Medicines</i> , 2021 , 75, 540-552	3.3	11
48	Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis. <i>ACS Applied Materials & Interfaces</i> , 2018 , 10, 36693-36702	9.5	11
47	The novel GLP-1/GIP dual receptor agonist DA3-CH is neuroprotective in the pilocarpine-induced epileptogenesis rat model. <i>Epilepsy Research</i> , 2019 , 154, 97-106	3	10
46	Block of HFS-induced LTP in the dentate gyrus by 1S,3S-ACPD: further evidence against LTP as a model for learning. <i>NeuroReport</i> , 1997 , 8, 451-4	1.7	10
45	Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021 , 41, 14-30	7.3	10
44	Evidence That Parietal Lobe Fatty Acids May Be More Profoundly Affected in Moderate Alzheimer's Disease (AD) Pathology Than in Severe AD Pathology. <i>Metabolites</i> , 2018 , 8,	5.6	10
43	Driving GABAergic neurons optogenetically improves learning, reduces amyloid load and enhances autophagy in a mouse model of Alzheimer's disease. <i>Biochemical and Biophysical Research Communications</i> , 2020 , 525, 928-935	3.4	8
42	Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2020 , 14, 614828	5.1	7
41	A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca homeostasis in 3xTg-AD mice. <i>Neuropharmacology</i> , 2020 , 170, 108042	5.5	7
40	A Novel Bioresorbable Device as a Controlled Release System for Protecting Cells from Oxidative Stress from Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2017 , 54, 6827-6838	6.2	7
39	A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice. <i>Hormones and Behavior</i> , 2020 , 118, 104640	3.7	7
38	Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model. <i>Neural Regeneration Research</i> , 2021 , 16, 1660-1670	4.5	7
37	Therapeutic potential of flavonoids in spinal cord injury. <i>Reviews in the Neurosciences</i> , 2017 , 28, 87-101	4.7	6

36	Metabotropic glutamate receptors control gating of spike transmission in the hippocampus area CA1. <i>Pharmacology Biochemistry and Behavior</i> , 2002 , 73, 307-16	3.9	6
35	Moving towards a more realistic concept of what constitutes Alzheimer's disease. <i>EBioMedicine</i> , 2019 , 39, 17-18	8.8	6
34	The novel GLP-1/GIP dual agonist DA3-CH is more effective than liraglutide in reducing endoplasmic reticulum stress in diabetic rats with cerebral ischemia-reperfusion injury. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 333-343	4.5	6
33	Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases. <i>International Review of Neurobiology</i> , 2020 , 155, 65-89	4.4	5
32	The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF- κ B inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01. <i>Brain and Behavior</i> , 2021 , 11, e2231	3.4	5
31	D-Ser2-oxynomodulin ameliorated A β 1-35-induced circadian rhythm disorder in mice. <i>CNS Neuroscience and Therapeutics</i> , 2020 , 26, 343-354	6.8	5
30	DA-JC1 improves learning and memory by antagonizing A β 1-35-induced circadian rhythm disorder. <i>Molecular Brain</i> , 2019 , 12, 14	4.5	4
29	Consciousness in mind: a correlate for ACh?. <i>Trends in Neurosciences</i> , 1999 , 22, 541-3	13.3	4
28	DAla2-GIP-GLU-PAL Protects Against Cognitive Deficits and Pathology in APP/PS1 Mice by Inhibiting Neuroinflammation and Upregulating cAMP/PKA/CREB Signaling Pathways. <i>Journal of Alzheimer's Disease</i> , 2021 , 80, 695-713	4.3	3
27	Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson's Disease Mouse Model. <i>Journal of Parkinson's Disease</i> , 2021 , 11, 529-543	5.3	2
26	A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021 , 83, 799-818	4.3	2
25	Synaptic plasticity and learning and memory: LTP and beyond 1999 , 58, 62		2
24	Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Parkinson's Disease Mouse Model.. <i>Frontiers in Neuroscience</i> , 2022 , 16, 814430	5.1	2
23	Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research.. <i>Frontiers in Neurology</i> , 2022 , 13, 844697	4.1	2
22	[P3063]: NOVEL BIODEVICE RELEASES DRUG IN VIVO FOR 14 DAYS AND AVOIDS DNA DAMAGE IN STRESS-INDUCED NEUROBLASTOMA CELLS: A PROMISE FOR ALZHEIMER'S DISEASE TREATMENT 2017 , 13, P955-P956		1
21	A GLP-2 Analogue Protects SH-SY5Y and Neuro-2a Cells Against Mitochondrial Damage, Autophagy Impairments and Apoptosis in a Parkinson Model. <i>Drug Research</i> , 2021 , 71, 43-50	1.8	1
20	P4-053: DUAL INCRETIN AGONIST REDUCES NEUROINFLAMMATION IN A TRANSGENIC MOUSE MODEL OF ALZHEIMER'S DISEASE 2018 , 14, P1453-P1453		1
19	Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and β synuclein accumulation in the colon of two Parkinson's disease mouse models.. <i>European Journal of Pharmacology</i> , 2022 , 175029	5.3	1

- 18 (D-Ser2) oxyntomodulin recovers hippocampal synaptic structure and theta rhythm in Alzheimer's disease transgenic mice.. *Neural Regeneration Research*, **2022**, 17, 2072-2078 4.5 ○
- 17 The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1 and TDP-43 transgenic mouse models of ALS. *Scientific Reports*, **2021**, 11, 17027 4.9 ○
- 16 The dual GLP-1/GIP receptor agonist DA4-JC shows superior protective properties in the APP/PS1 mouse model of Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, e039220 1.2
- 15 P4-317: Liraglutide protects the brains of macaques against synapse loss caused by abeta oligomers **2015**, 11, P905-P906
- 14 Roles of Glucagon-Like Peptide and Glucose-Dependent Insulinotropic Polypeptide Hormones in Brain Function and Neurodegeneration **2012**, 351-373
- 13 How could populations of neurons encode information?3-18
- 12 Theta rhythm and bidirectional plasticity in the hippocampus174-191
- 11 Distributed population codes in sensory and memory representations of the neocortex192-223
- 10 Functional roles of theta and gamma oscillations in the association and dissociation of neuronal networks in primates and rodents151-173
- 9 Summary of chapters, conclusion, and future targets433-469
- 8 Introduction: Long-Term Potentiation as a Model for Memory Mechanisms: The Story So Far **2000**, 1-34
- 7 Conclusions and Future Targets **2000**, 476-490
- 6 Theta-Facilitated Induction of Long-Term Potentiation: A Better Model for Memory Formation? **2000**, 146-166
- 5 Motor Information is Integrated with Spatial Sensory Information in the Hippocampus **2019**, 400-400
- 4 Rats are Able to Navigate Successfully in Virtual Reality Environments **2019**, 399-399
- 3 P3-076: QUANTITATIVE METABOLOMICS PROFILING OF BRAIN TISSUE FROM PEOPLE WHO SUFFERED FROM MILD AND SEVERE AD REVEALS DISTINCT BIOCHEMICAL DIFFERENCES WHEN COMPARED TO TISSUE HARVESTED FROM NON-COGNITIVELY IMPAIRED PEOPLE **2018**, 14, P1093-P1094
- 2 P3-067: POLY(LACTIC ACID) (PLA) ELECTROSPUN FIBERS IMPROVE NEUROGENESIS AND REDUCE AMYLOID PLAQUES IN A TRANSGENIC MOUSE MODEL OF ALZHEIMER'S DISEASE **2018**, 14, P1090-P1090
- 1 033 GLP-1RAs reduce stroke incidence in patients with type 2 diabetes mellitus: a meta-analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2022**, 93, A111.1-A111 5.5

